- Home
- JPC vs CNTA Comparison
JPC vs CNTA Comparison
Compare JPC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JPC
- CNTA
- Stock Information
- Founded
- JPC 2003
- CNTA 2020
- Country
- JPC United States
- CNTA United Kingdom
- Employees
- JPC N/A
- CNTA N/A
- Industry
- JPC Investment Managers
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- JPC Finance
- CNTA Health Care
- Exchange
- JPC Nasdaq
- CNTA Nasdaq
- Market Cap
- JPC 2.6B
- CNTA 2.2B
- IPO Year
- JPC N/A
- CNTA 2021
- Fundamental
- Price
- JPC $8.01
- CNTA $16.87
- Analyst Decision
- JPC
- CNTA Strong Buy
- Analyst Count
- JPC 0
- CNTA 8
- Target Price
- JPC N/A
- CNTA $23.17
- AVG Volume (30 Days)
- JPC 998.5K
- CNTA 1.0M
- Earning Date
- JPC 01-01-0001
- CNTA 03-27-2025
- Dividend Yield
- JPC 7.57%
- CNTA N/A
- EPS Growth
- JPC N/A
- CNTA N/A
- EPS
- JPC N/A
- CNTA N/A
- Revenue
- JPC N/A
- CNTA $6,853,000.00
- Revenue This Year
- JPC N/A
- CNTA N/A
- Revenue Next Year
- JPC N/A
- CNTA N/A
- P/E Ratio
- JPC N/A
- CNTA N/A
- Revenue Growth
- JPC N/A
- CNTA N/A
- 52 Week Low
- JPC $5.94
- CNTA $7.75
- 52 Week High
- JPC $7.36
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- JPC 51.05
- CNTA 52.95
- Support Level
- JPC $7.92
- CNTA $15.30
- Resistance Level
- JPC $8.05
- CNTA $17.29
- Average True Range (ATR)
- JPC 0.05
- CNTA 1.10
- MACD
- JPC 0.00
- CNTA 0.11
- Stochastic Oscillator
- JPC 65.38
- CNTA 67.37
About JPC Nuveen Preferred & Income Opportunities Fund
Nuveen Preferred & Income Opportunities Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. It invests its managed assets in preferred securities, and in other types of securities, primarily income-oriented securities such as corporate and taxable municipal debt and common equity.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.